Search

Your search keyword '"peripherally acting mu-opioid-receptor antagonist"' showing total 2 results
Start Over Descriptor "peripherally acting mu-opioid-receptor antagonist"
2 results on '"peripherally acting mu-opioid-receptor antagonist"'

1. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem.

Author

Yoon, Stephanie C. and Bruner, Heather C.

Subjects
*OPIOID-induced constipation, *CONSTIPATION, *THERAPEUTICS, *QUALITY of life, *GASTROINTESTINAL system, *OPIOIDS
Abstract

Opioid-induced constipation (OIC) imposes a significant burden for patients taking pain medications, often resulting in decreased quality of life. Treatment of OIC with traditional medications for functional constipation can be incompletely effective, leading to nonadherence with opioid treatment and undertreated pain. An emerging class of medications that counteract the adverse effects of opioids in the gastrointestinal tract while preserving central nervous system-based pain relief may represent a paradigm shift in the prevention and treatment of OIC. One of these medications, naloxegol, is a once-daily, oral opioid antagonist that is effective, well-tolerated, and approved for treatment of OIC in patients with noncancer pain. More studies are needed to demonstrate this same utility in patients with cancer-related pain. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

2. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem

Author

Heather C Bruner and Stephanie C Yoon

Subjects
medicine.medical_specialty, Constipation, medicine.drug_class, Medicine (miscellaneous), Review, peripherally acting mu-opioid-receptor antagonist, 03 medical and health sciences, Naloxegol, chemistry.chemical_compound, OIBD, 0302 clinical medicine, medicine, Intensive care medicine, Adverse effect, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), business.industry, Health Policy, Chronic pain, bowel care, medicine.disease, opioid-induced constipation, chemistry, Opioid, 030220 oncology & carcinogenesis, Functional constipation, Bowel care, medicine.symptom, chronic pain, business, 030217 neurology & neurosurgery, Social Sciences (miscellaneous), Opioid antagonist, medicine.drug
Abstract

Opioid-induced constipation (OIC) imposes a significant burden for patients taking pain medications, often resulting in decreased quality of life. Treatment of OIC with traditional medications for functional constipation can be incompletely effective, leading to nonadherence with opioid treatment and undertreated pain. An emerging class of medications that counteract the adverse effects of opioids in the gastrointestinal tract while preserving central nervous system-based pain relief may represent a paradigm shift in the prevention and treatment of OIC. One of these medications, naloxegol, is a once-daily, oral opioid antagonist that is effective, well-tolerated, and approved for treatment of OIC in patients with noncancer pain. More studies are needed to demonstrate this same utility in patients with cancer-related pain.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results